摘要
目的观察吉非替尼联合适形放射治疗局部晚期非小细胞肺癌（NSCLC）的疗效及副反应。方法 40例局部晚期NSCLC患者随机分为吉非替尼联合适形放射治疗组（治疗组）和单纯适形放射治疗组（对照组）各20例。放疗采用6/15MV X线三维适形放射治疗,2.0~2.5 Gy次/,1次/d,5次/周,DT66~76 Gy。治疗组同步口服吉非替尼,从放疗第1天开始,连服2个月。结果治疗组与对照组有效率（CR＋PR）分别为85.0%和60.0%（χ2=3.33,P〉0.05）;1,2年生存率分别为70.0%、35.0%和45.0%、20.0%（χ2=2.56,1.13,P〉0.05）。吉非替尼组痤疮样皮疹发生率为55.0%,多为轻、中度,腹泻多为轻度。结论吉非替尼联合适形放射治疗局部晚期非小细胞肺癌的疗效较好,毒副反应较轻,可以耐受。
Objective To evaluate the efficacy and toxicity of gefitinib combined with three dimensional conformal radiotherapy（3DCRT）for treatment of locally advanced non-small cell lung cancer（LA-NSCLC）.Methods Forty patients with LA-NSCLC were randomized into two groups：twenty patients received gefitinib plus 3DCRT（treatment group）,20 received 3DCRT（control group）.All patients were given 6/15MV X-ray 3DCRT,2.0-2.5Gy per fraction,once daily.The total dose was DT 66-76 Gy.Gefitinib was administered concurrently with radiotherapy in escalating doses from the 1 st day of RT to two months.Results The effective rates（CR＋PR）in treatment group and control group were 85.0% and 60.0%（χ2=3.33 P0.05）;1-and 2-year survival rates were 70.0%,35.0% and 45.0%,20.0%（χ2=2.56,1.13 P0.05）.Skin rash rate in gifitivib group was 55.5%.There was no significant relationship between rash severity and response.Diarrhea was mild and self-limited.Conclusion The results suggest that gefitinib and 3DCRT in treatment of patients with LA-NSCLC has good efficacy and well-tolerated toxicity.
出处
《中国肿瘤临床与康复》
2011年第3期256-257,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
肺肿瘤
吉非替尼
三维适形放射治疗
Lung noplasms
Gefitinib
Three dimensional conformal radiotherapy
